Join
Live feed
·
PRReleasevia Quantisnow
Spyre Therapeutics Inc. logo

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

ByQuantisnow·Wall Street's wire, on your screen.
SYRE· Spyre Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRE (Spyre Therapeutics Inc.) and more on Quantisnow.